Gary Clark: Unfiltered

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

Stewart Information Services is raising millions via a stock offering. We analyze the strategy, the market signals, and the impact on shareholder value.

The packaging giant pushed its debt wall to 2030 and stripped key covenants. We analyze the strategic brilliance and the high-stakes bargain for investors.

The REIT's strategic land sale accelerates its deleveraging, but the deal's true impact lies in its transformation and the future of Jersey City's skyline.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

Fintech firm Nayax's oversubscribed Israeli offering signals strong investor confidence and fuels its ambitious plan for global expansion through acquisitions.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

Borr Drilling leverages complex debt and equity financing to acquire five premium rigs, a high-stakes bet on a strengthening offshore drilling market.

A V2G pioneer pivots its intelligent software to compete for a massive national energy storage contract in South Korea's booming, high-stakes market.

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

Beyond webinars, ON24's G2 win and LinkedIn pact reveal a strategic shift to AI-driven data and connected campaigns in the B2B marketing tech war.

Quantum Computing Inc. is leaving the lab for Las Vegas, betting its US-made photonic chips can solve real-world AI problems and justify a lofty valuation.

A Hong Kong award for Youxin Technology offers a deeper look into the firm's strategic acquisition, its role in the GBA, and what it means for investors.

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.

The space firm secures vital cash through a complex warrant deal, but at what cost to shareholders? All eyes are now on a critical investor vote.